ACTG vs CYRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACTG exhibits severe financial health concerns, evidenced by a Piotroski F-Score of 2/9 (indicating weak fundamentals) and a missing Altman Z-Score, which raises distress risk concerns. Despite a Graham Number of $2.76 suggesting undervaluation, the stock trades at $4.88, implying a premium driven by speculative growth expectations. The company shows erratic earnings performance with massive EPS surprises, including a -2247% miss in 2022 and a 1587% beat in 2021, signaling extreme inconsistency. Profitability remains weak, with negative operating margins (-26.1%) and low ROE (4.31%), while revenue growth is minimal (2.6% YoY). The technical trend is bearish (10/100), and insider activity is neutral, offering no conviction.
CYRX shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACTG vs CYRX: Head-to-Head Comparison
This page compares Acacia Research Corporation (ACTG) and Cryoport, Inc. (CYRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.